Phase 3CompletedAge-related condition

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause

Sponsor
Noven Therapeutics (Industry)
Enrollment
570 enrolled
Conditions
Hot Flashes
Interventions
Brisdelle (paroxetine mesylate); Placebo capsules
Ages
adults, older adults
Registry
NCT01101841

Full record on ClinicalTrials.gov

From the registry

To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause

Primary outcomes

  • Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12.
  • Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12.

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started